Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693768 | 0.77 | USP2 (0.50) | NAMPT | |
| SCHEMBL14108540 | 0.76 | — | — | |
| SCHEMBL21828411 | 0.73 | NAMPT (0.40) | NAMPT | |
| SCHEMBL22799086 | 0.70 | NAMPT (0.35) | NAMPT | |
| SCHEMBL28444655 | 0.70 | — | — | |
| SCHEMBL22615930 | 0.69 | HRH3 (0.40) | NAMPT | |
| SCHEMBL15655020 | 0.69 | HRH3 (0.40) | NAMPT | |
| SCHEMBL21631637 | 0.69 | NAMPT (0.34) | NAMPT | |
| SCHEMBL16914259 | 0.69 | NAMPT (0.34) | NAMPT | |
| SCHEMBL3173644 | 0.69 | SPR (0.39) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230219946-A1 | PYRIMIDIN-4(3H)-ONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-13 | — | — | US | disclosed |
| EP-4092024-A1 | PYRIMIDINE-4(3H)-KETONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE AND PHARMACOLOGY | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-11-15 | — | — | US | disclosed |
| EP-3463343-B1 | HETEROCYCLIC INHIBITORS OF PTPN11 | UNIV TEXAS (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | Cantero Therapeutics, Inc. | 2021-10-14 | — | — | US | disclosed |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3310774-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| EP-3310771-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| EP-3310779-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2017210134-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-11-30 | — | — | US | disclosed |
| WO-2016203405-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203406-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| EP-3094628-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2016-11-23 | — | — | EP | disclosed |
| WO-2015107495-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2015-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | NAMPT 1073/4885 |
| US-11498930-B2 | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof | PTPN11, PPM1F, PTPRF | NAMPT 388/4885 |
| US-20230109858-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | NAMPT 1073/4885 |
| US-10954243-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | NAMPT 1094/4885 |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | NAMPT 1094/4885 |
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | PTPN11, PPM1F, PTPRF | NAMPT 388/4885 |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | PTPN11, PTPRJ, PTPRCAP | NAMPT 1094/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | NAMPT 1073/4885 |
| US-20230219946-A1 | PYRIMIDIN-4(3H)-ONE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | PTPN5, PTPN1, JAK2 | NAMPT 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.